Iktos is a French start-up company which develops a truly innovative and disruptive artificial intelligence technology for ligand-based de novo drug design, focusing on MPO (multi parametric optimization).

Our innovative algorithm is based on state of the art deep learning models, called generative models, and enables to design new, druggable and synthesizable molecules under the constraint of a given blueprint, with unprecedented speed and performance.